Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the 2021 version: 

 

Please note: The entire guideline document was last updated in 2021 and does not contain the latest information on the individual chapters. Below you can find the individual chapters that have been successively updated in the meantime. They will be incorporated into the entire guideline document when the updating process is completed.

Last updated
Changes
Download
Introduction, scoping, population and targeted users
10/2021
We welcome Ivan Bogdanov, Liam Mercieca and Dimitris Rigopoulos to the group.
Disease severity and treatment goals
10/2021
No changes
Methods and evidence section
12/2021
Editorial changes
Main Recommendations and Decision Grid
10/2021
Bimekuzumab was added; guselkumab and PsA was added.
Implementation slides
10/2021
Bimekuzumab was added; guselkumab and PsA was added
IFPA Guideline
10/2021
No changes

Last updated
Changes
Download
Acitretin
03/2023
No changes
Ciclosporin
03/2023
Reference added
Fumarates
03/2023
No changes
Methotrexate
03/2023
New data added
Adalimumab
03/2023
No changes
Apremilast
03/2023
New data added
Bimekizumab
10/2021
New chapter
Brodalumab
10/2021
Section on IBD updated
Certolizumab – Pegol
10/2021
No changes
Etanercept
03/2023
No changes
Guselkumab
03/2023
No changes
Infliximab
03/2023
No changes
Ixekizumab
10/2021
No changes
Risankizumab
10/2021
No changes
Secukinumab
10/2021
No changes
Tildrakizumab
03/2023
No changes
Ustekinumab
03/2023
No changes
Biosimilars
10/2021
No changes
Newly approved medications and treatments in the pipeline
10/2021
No changes

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Cancer
10/2021
Editorial changes
Depression
10/2021
No changes
Diabetes Mellitus
10/2021
No changes
Heart disease
03/2023
New data added
Kidney disease
03/2023
New data added
Neurological diseases
10/2021
New data on ixekizumab added
Viral Hepatitis
10/2021
No / update in progress
Tuberculosis: Screening
10/2021
Editorial changes
Tuberculosis: Treatment
10/2021
Editorial changes
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Vaccinations
03/2023
Completely new written
Inmunogenicity
10/2021
No changes

Last updated
Changes
Download
Methods Report
10/2021
No changes
Strength and limitations
10/2021
No changes
References
10/2021
Added new references
Abbreviations
10/2021
No changes